Blog Illumina Cybersecurity Vulnerability May Present Risks for Patient Results and Customer Networks by CGI | Jun 2, 2022read more FDA Safety Communication for Patients and Healthcare Providers on NIPS by CGI | Apr 20, 2022read more FDA Control of Laboratory Developed Tests (LDTs) Building Momentum with VALID Act by CGI | Mar 16, 2022read more Natera and CareDx Fined Millions for False Advertising Associated with Inappropriate Marketing for Testing by CGI | Mar 15, 2022read more Natera Minimal Residual Disease (MRD) Test Value Questioned by City of Hope for Colorectal Cancer Patients by CGI | Mar 9, 2022read more Next Entries »
Illumina Cybersecurity Vulnerability May Present Risks for Patient Results and Customer Networks by CGI | Jun 2, 2022read more
FDA Safety Communication for Patients and Healthcare Providers on NIPS by CGI | Apr 20, 2022read more
FDA Control of Laboratory Developed Tests (LDTs) Building Momentum with VALID Act by CGI | Mar 16, 2022read more
Natera and CareDx Fined Millions for False Advertising Associated with Inappropriate Marketing for Testing by CGI | Mar 15, 2022read more
Natera Minimal Residual Disease (MRD) Test Value Questioned by City of Hope for Colorectal Cancer Patients by CGI | Mar 9, 2022read more